We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Health and Fitness

Rightangled Ltd.

Status: Active

May 7th 2020 - Jun 6th 2020

Rightangled is a healthcare technology company backed by NHS England & regulated by the Care Quality Commission (CQC). It began its journey as a platform that would enable the use of genetic information within the medical practice, in an accurate, streamlined, and affordable way. It gradually established itself as a healthcare provider for screening and diagnostic services. Its Heart DNA Test project, launched in 2017, is helping patients minimize their cardiac risks and enabling doctors to have a complete risk profile for their patients. The project was appreciated and received funding from NHS England. Its next project, Fitness DNA Test, tapped into the fitness and wellbeing markets. Recently, in the wake of the COVID-19 threat, the company has developed a home-based throat swab test to detect the viral infection, by testing viral load presented in its nucleic acid material within (RNA). For its efforts, Rightangled has been featured on CNN, Sky News, LBC radio, Sky News radio, and Newsweek. With the investment, the company aims to release a mobile application by the end of 2020, and develop an AI system to give instant tailored health, diet, and fitness advice to its users based on the data gathered from patient-doctor interactions and patient responses.

read more read less

Rightangled Ltd. Rating Review

Pitch rating powered by CROWDRATING

Rated on 22/05/2020

Pitch Rated

81%

Gold

Management

87%

Product

81%

Investment

75%

Log in to view amount pledged

    Log in to view target

    £9,500,000
    pre-money valuation

    0.52%
    equity available

    1,277
    investors

    £409
    pledge per investor

    09866557
    company number

    Active
    company status

    11/11/2015
    incorporated 9 years

    £0.22
    share price

    Previous Funding rounds
    28 Apr 24 Crowdcube £522,689 / 1,045% 81.00%

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 87%

Skills 91%
Rightangled Ltd has a skilled and diverse team in place covering the roles of operations, marketing, platform development and finance. The team is led by a CEO who is skilled in Business Development, Project Planning and Management, Strategic Planning, Social media Networking, and Business Strategy. He has also been awarded the "Innovation and Entrepreneurship" in 2016. The Head of IT has expertise in Agile Methodologies, Scrum, Enterprise Architecture, ASP.NET, Ruby on Rails, SQL, CSS, and JavaScript. The Partnerships Manager is a Medical Professional skilled in Aesthetics, Healthcare, Clinical Research, Endodontics, and Prosthodontics. He is responsible for developing commercial and strategic relationships with local health entities in the UK. The Head of Finance has expertise in financial analysis, corporate restructuring, tax and strategic business planning.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


More from Health and Fitness

PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001

Log in to view amount pledged

    Log in to view target

    £9,500,000
    pre-money valuation

    0.52%
    equity available

    1,277
    investors

    £409
    pledge per investor

    09866557
    company number

    Active
    company status

    11/11/2015
    incorporated 9 years

    £0.22
    share price

    Previous Funding rounds
    28 Apr 24 Crowdcube £522,689 / 1,045% 81.00%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph